Earlyin vivoassessment of angiostatic therapy efficacy by molecular MRI
- 3 January 2007
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 21 (2) , 378-383
- https://doi.org/10.1096/fj.06-6791com
Abstract
Noninvasive diagnostic imaging methods to establish the efficacy of angiostatic therapies are becoming increasingly important with the first Food and Drug Administration approvals of such agents. Magnetic resonance molecular imaging is an imaging technique that allows the visualization of pathological processes in vivo with a better spatial resolution as compared with nuclear methods, such as photon emission tomography and single photon emission computed tomography. In this study, we used αvβ3 targeted bimodal liposomes to quantitate angiogenesis in a tumor mouse model with magnetic resonance imaging (MRI) and to evaluate the therapeutic efficacy of the angiogenesis inhibitors anginex and endostatin. The MRI findings were validated with fluorescence microscopy and showed a very good correlation with the microvessel density. In conclusion, this study provides evidence that molecular MRI can be used to noninvasively measure the efficacy of angiogenesis inhibitors during the course of therapy.—Mulder, W. J. M., van der Schaft, D. W. J., Hautvast, P. A. I., Strijkers, G. J., Storm, G., Mayo, K. H., Griffioen, A. W., Nicolay, K. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI.Keywords
This publication has 21 references indexed in Scilit:
- Use of SU11248 to inhibit proangiogenic growth factors in renal-cell carcinoma patientsNature Clinical Practice Oncology, 2006
- MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticleThe FASEB Journal, 2005
- Endostatin: The logic of antiangiogenic therapyDrug Resistance Updates, 2005
- Endogenous angiogenesis inhibitorsAPMIS, 2004
- A Liposomal System for Contrast-Enhanced Magnetic Resonance Imaging of Molecular TargetsBioconjugate Chemistry, 2004
- Endostatin's endpoints—Deciphering the endostatin antiangiogenic pathwayCancer Cell, 2004
- The designer antiangiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal modelsThe FASEB Journal, 2002
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Scaling down imaging: molecular mapping of cancer in miceNature Reviews Cancer, 2002
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993